Médecine

Paramédical

Autres domaines


S'abonner

Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States - 09/02/13

Doi : 10.1016/j.jaad.2012.07.027 
Irene Cosmatos, MS a, Amy Matcho, BA a, Rachel Weinstein, PhD a, , Michael O. Montgomery, MD b, Paul Stang, PhD a
a Janssen Research and Development LLC, Titusville, New Jersey 
b Janssen Services LLC, Horsham, Pennsylvania 

Reprint requests: Rachel Weinstein, PhD, Janssen Research and Development LLC, 1125 Trenton-Harbourton Rd, PO Box 200, Titusville, NJ 08560.

Abstract

Background

Recent prevalence estimates for hidradenitis suppurativa (HS), a chronic inflammatory skin condition, are limited by timeliness, population size, and generalizability.

Objective

We sought to develop prevalence estimates for HS in the United States using large health care claims databases.

Methods

A retrospective analysis used PharMetrics Integrated Database to gather health care claims information for HS among patients with 12 or more months of continuous enrollment in a commercial health care plan throughout 2007. Included patients had: 1 or more diagnoses with International Classification of Diseases, Ninth Revision, Clinical Modification code 705.83 for HS during 2007 without a Current Procedural Terminology code for HS; 1 or more Current Procedural Terminology codes of 11450, 11451, 11462, 11463, 11470, or 11471 during 2007 without International Classification of Diseases, Ninth Revision, Clinical Modification code 705.83; or both. Age- and gender-specific prevalence projections were calculated.

Results

Among included patients (n = 7927), mean age (SD) was 38.2 (14.73) years, and 5834 (74%) were women. Most patients (n = 5205; 66%) were aged 30 to 64 years. The overall prevalence estimate was 0.053% (95% confidence interval 0.051-0.054). When adjusted for gender and age, prevalence rates were 0.052% and 0.051%, respectively. The most common procedures for HS were excision of skin and subcutaneous tissue axillary/inguinal simple or intermediate repair.

Limitations

Limitations were a health insured–only population; 12-month enrollment period for 2007; HS-specific procedural codes; and possible HS misclassifications.

Conclusion

We found a low rate of clinically detected HS (0.053%; approximately 146,000-162,000 patients in the United States in 2007), with affected persons almost 3 times as likely to be female and the highest prevalence in those aged 18 to 44 years.

Le texte complet de cet article est disponible en PDF.

Key words : acne inversa, apocrine, epidemiology, hidradenitis suppurativa, prevalence

Abbreviations used : CPT, HS, ICD-9-CM


Plan


 Ms Cosmatos is currently affiliated with IMS Health Inc, Parsippany, NJ.
 Supported by Janssen Services LLC.
 Disclosure: Dr Montgomery was an employee of Janssen Services LLC, at the time of this research, and Dr Stang, Ms Cosmatos, Ms Matcho, and Dr Weinstein are or were employees of Janssen Research and Development LLC.
 Conflicts of interest: None declared.


© 2012  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 68 - N° 3

P. 412-419 - mars 2013 Retour au numéro
Article précédent Article précédent
  • Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients
  • Yael A. Leshem, Emmilia Hodak, Michael David, Grant J. Anhalt, Daniel Mimouni
| Article suivant Article suivant
  • Histopathology and correlates of systemic disease in adult Henoch-Schönlein purpura: A retrospective study of microscopic and clinical findings in 68 patients at Mayo Clinic
  • Timothy J. Poterucha, David A. Wetter, Lawrence E. Gibson, Michael J. Camilleri, Christine M. Lohse

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.